



Supplementation for sarcopenia in chronic kidney disease updated literature review

Suplementação para sarcopenia em doença renal crônica revisão atualizada da literatura

DOI: 10.56238/isevjhv2n5-024

Receipt of originals: 10/05/2023

Acceptance for publication: 10/25/2023

Amabillé Yoshimi Tiunan

Graduating from the Faculty of Medicine of the University of Contestado,
E-mail: amabilletiuman@gmail.com

Rafael Falavigna

Graduating from the Faculty of Medicine of the University of Contestado
E-mail: rafael6543@yahoo.com.br

Tatiane Rosa de Lima

Graduating from the Faculty of Medicine of the University of Contestado
E-mail: tatiane.santiago1603@gmail.com

Marco Antonio Schueda

Ph.D. Professor and Coordinator of the Faculty of Medicine of the University of Contestado
E-mail: schueda.sc@gmail.com

Study carried out at the Faculty of Medicine of the University of Contestado - UNC Campus de Mafra - Santa Catarina

ABSTRACT

Sarcopenia is the loss of muscle mass and strength, common in elderly patients and worsened by the presence of chronic kidney disease (CKD), which has a progressive decrease in the number of nephrons. Anaerobic physical exercise and protein supplementation are important for maintaining strength and muscle mass. Dietary interventions, such as greater protein intake, are essential to preserve and increase muscle mass. Leucine appears to be the most powerful amino acid in stimulating muscle anabolism. Testosterone and L-carnitine supplementation may also be helpful, but there is controversy regarding their use. Omega 3, vitamin D and calcium are supplements that can increase muscle mass and improve muscle function in patients with sarcopenia associated with CKD, but their dosages are still debatable. This review article aims to describe oral supplementation for sarcopenia and the kidney changes that they may cause. In summary, physical activity and protein supplementation are fundamental in the treatment of sarcopenia in patients with CKD.

Keywords: Sarcopenia, Chronic kidney disease, Supplementation, Elderly.



1 INTRODUCTION

Chronic kidney disease is a pathology with a multifactorial cause, which occurs because of irreversible alterations in renal function and physiology¹.

It occurs slowly, silently, and progressively. Incidence and prevalence are associated in the older population¹.

Renal function is verified through the glomerular filtration rate, which gives us the total amount of filtrate per unit of time, so in CKD there is a decrease in this filtration². The loss of regulatory, excretory and endocrine functions of the kidney end up evolving with several complications, among them, we highlight sarcopenia, which is a progressive loss of tissue and muscle function associated with the aging process, but which is associated with CKD, and may be present from the early stages that worsens with the progression of the disease^{2, 3·4}.

Because of this, it is important to diagnose and treat sarcopenia early in patients with chronic kidney disease, anticipating an unfavorable outcome. The presence of sarcopenia in individuals with CKD is associated with poor quality of life, increased likelihood of falls, cardiovascular events, and higher morbidity and mortality.

Currently, treatments available to improve sarcopenia include:

- Personalized physical activity program
- Pharmacological treatment
- Nutritional therapy (oral nutritional supplement)^{3, 5}.

The objective of this review is to survey the articles, mainly from the last five years, related to the non-pharmacological treatment of sarcopenia and the renal alterations that they may determine.

2 METHODOLOGY

The methodology chosen to carry out this research was a literature review with an exploratory approach.

For Marconi and Lakatos (2019), literature reviews have the purpose of putting the researcher in direct contact with everything that has been written, said or filmed on the subject. It is not a mere repetition of the subject, but provides an analysis of the theme from another point of view or approach, in order to reach new conclusions⁶.

The research followed the recommended methods, after choosing the theme and preliminary research. The samples, were read, selected, evaluated and analyzed. The



characteristics of the research were defined and then the results were discussed, interpreted and presented.

3 MATERIAL AND METHODS

This study was based on 15 articles in national and international publications, preferably in the last 5 years, in the PubMed, Scholar Google and Scielo databases, using the following keywords: sarcopenia, CKD, supplementation and elderly.

4 RESULTS AND DISCUSSIONS

The data found in the exploration of these articles showed:

The elderly population is considered a risk group for CKD, where it has been evidenced in the presence of chronic kidney injury, where we have verified a progressive decrease in the number of nephrons with an estimated loss of about 48% up to 75 years of age⁷. For this, two parameters are evaluated, the serum creatinine level (CrS) and the amount of urine output, in order to diagnose chronic kidney disease⁷.

Sarcopenia is common in elderly patients and is aggravated in the presence of CKD⁷. The parameters of loss of muscle mass and strength are used, in which they show that, over the age of 50, muscle mass decreases by 1 to 2% per year, while muscle strength decreases at a rate of 1.5% per year, increasing to 3% at age 60. In the general population, the prevalence of sarcopenia in adults, aged 60 to 70 years, ranges from 5 to 13%, increasing to 11 to 50% in those aged 80 years and older. In patients with CKD, the reported prevalence of sarcopenia ranges markedly from 3.9% to 98.5%⁸.

4.1 SARCOPENIA IN CHRONIC KIDNEY DISEASE

Progressive load-bearing exercise training can induce improvements in sarcopenia and health-related quality of life. It reinforces that physical exercise and protein supplementation are essential interventions to maintain strength and skeletal mass^{3,8}.

Sarcopenia is more common in advanced age, but in patients with CKD it is aggravated due to the prevalence of a uremic state leading to metabolic acidosis, reduced protein synthesis and increased protein degradation, producing a positive nitrogen balance^{8,9}. In CKD, in addition to the development of metabolic acidosis, this persistent catabolic state causes an increase in insulin resistance and a decrease in anabolic hormones, for example: Gh; IGF1; testosterone, in addition to vitamin D^{deficiency7,8,9,10}.



The pro-inflammatory state is probably the most common cause of muscle tissue depletion. Cytokines activate the transcription of nuclear factor NF Kapa-B, which results in decreased muscle protein synthesis, TNF-alpha is highly specific for stimulating the proteolysis of heavy-chain myosin. In addition, cytokines stimulate the release of cortisol and catecholamines from the adrenal gland. As a result, it results in muscle loss and atrophy^{7,8,9}.

4.2 NUTRITIONAL SUPPLEMENTATION

Dietary interventions are essential to preserve muscle mass and promote its elevation, providing an energy and protein load to recover the adequate nutritional status for the health of patients who already have established CKD, especially when the processes of mass and strength reduction are already taking place^{1,9}. The recommended daily requirement of protein intake for CKD patients is twice as high as that of the general elderly population⁸.

Authors recommend a protein intake of 0.6 to 0.8 g/kg body weight per day (in stages III-V) without presenting a deficit for glomerular filtration rate^{1,9,10} and the introduction of 2 servings of WP-MND (21g of protein, 3g of leucine, 10 µg of vitamin D and 500 mg of calcium) for a period of 6 months. did not result in deterioration of renal function and no vitamin D or calcium toxicity, the product was overall well tolerated².

The use of leucine as a supplement stimulates muscle protein synthesis in older patients, being considered the most potent amino acid in stimulating muscle anabolism and inhibiting catabolism¹⁰.

As for testosterone, its use is indicated from the weekly dosage of 100mg of Nandrolone for a period of 24 weeks, there will be an increase in appendicular lean mass in two times. But we should look at testosterone replacement, especially in women ^{11, 12}.

On the other hand, according to *Sabatino et al* (2021), protein supplementation in elderly patients with stage III to V CKD is still a subject to be debated due to controversies¹⁰.

A co-ingestion of leucine with a bolus of dietary protein for a supplementation period of 16 weeks will stimulate protein synthesis. 2.5g – 3.0g of leucine associated with about 25 to 30g of protein was analyzed to increase anabolism, through the mTOR signaling pathway: ribosomal kinase of 70 kDA - p70S6k; eukaryotic initiation factor 4E - 4E-BP1 and eukaryotic initiation factor 4G - eIF4G have been shown to increase muscle mass^{10,11,13}.

Although L-carnitine supplementation significantly increases muscle area in CKD patients, exercise seems to be the therapeutic action with the highest result in the population with sarcopenia



associated with advanced kidney disease, and nutritional and pharmacological interventions lack effective proof^{14,15}.

Reports mention that large protein supplementations tend to decline renal function, generating renal hyperfiltration and hyperemia, accelerating chronic kidney disease, associated with several metabolic alterations¹⁶.

The use of omega-3 fatty acids in elderly patients with CKD-associated sarcopenia increases muscle mass, reduces oxygen demand during physical activity, and prevents muscle catabolism^{4,11}. Anabolism occurs through the ingestion of 1g - 2 g of omega 3 at intervals of up to 150 days (acting on the mTOR-p70s6k signaling pathway) concomitantly with anaerobic physical exercise¹¹.

Vitamin D supplementation, which is essential for calcium absorption, resulted in the improvement of muscle trophism and minimizing falls, at a dosage of 1,200mg – 1,500mg/day^{11,12}.

The association of calcium with vitamin D strengthens musculoskeletal function (calcium carbonate 1,200mg - 1,500mg/day), which is essential to meet the deficiency of sarcopenic patients with CKD^{17,18}.

From the analysis of the various opinions, we noticed that the less recent articles recommended the need for a double dose of protein supplements, but that they would cause worsening of renal function^{8,15}. Current studies show that leucine supplementation is more effective in preserving renal function^{2,10,11}.

Anaerobic physical activity is a consensus, and it is necessary for the effectiveness of protein supplementation^{3,7,8,11,12,13,15}.

Vitamin D, omega-3 and calcium supplementation are important as adjuvants in the treatment of sarcopenia in CKD^{4,11,12,17,18}.

5 CONCLUSION

After analyzing the articles dealing with the non-pharmacological treatment of sarcopenia in CKD, we found a consensus on the indication of anaerobic physical activities associated with supplementation.

The emphasis was on protein supplementation based on leucine, due to its efficacy in stimulating muscle trophism, in addition to being the one that least harms renal function.



The use of other supplements, omega 3, vitamin D and calcium are also effective when administered adjunctly, however, more studies are still needed focusing on their doses and mechanism of action.



REFERENCES

Donato, Beatriz, *et al.* Nutricionista. (2021). Sarcopenia na doença renal crônica – Uma breve revisão. revista portuguesa de nefrologia e hipertensão, doi: 10.32932/PJNH.2021.07.129

Bauer JM, Mikušová L, Verlaan S, Bautmans I, Brandt K, Donini LM, Maggio M, Mets T, Wijers SLJ, Garthoff JA, Luiking Y, Sieber C, Cederholm T; PROVIDE Consortium. Safety and tolerability of 6-month supplementation with a vitamin D, calcium and leucine-enriched whey protein medical nutrition drink in sarcopenic older adults. *Aging Clin Exp Res.* 2020 Aug;32(8):1501-1514. doi: 10.1007/s40520-020-01519-x. Epub 2020 Mar 12. PMID: 32162241; PMCID: PMC7452877.

Noor H, Reid J, Slee A. Exercício resistido e intervenções nutricionais para aumentar os desfechos de sarcopenia na doença renal crônica: uma revisão narrativa. *J Caquexia Sarcopenia Músculo.* 2021 Dez; 12(6):1621-1640. DOI: 10.1002/jcsm.12791. Epub 2021 28 de setembro. PMID: 34585539; PMCID: PMC8718072.

Boia Stella A, Gortan Cappellari G, Barazzoni R, Zanetti M. Atualização sobre o impacto dos ácidos graxos ômega 3 na inflamação, resistência à insulina e sarcopenia: uma revisão. *Int J Mol Sci.* 2018 11 de janeiro; 19(1):218. DOI: 10.3390/ijms19010218. PMID: 29324650; PMCID: PMC5796167.

Yoshida S, Shiraishi R, Nakayama Y, Taira Y. A nutrição pode contribuir para a redução da sarcopenia, fragilidade e comorbidades em uma sociedade superidosa? *Nutrientes.* 2023 jun 30; 15(13):2991. DOI: 10.3390/nu15132991. PMID: 37447315; PMCID: PMC10346954.

Marconi MA, Lakatos EM. *Fundamentos de Metodologia Científica.* São Paulo – SP, 8ª ed. Atlas, pg200,2019.

PAIXÃO, Daniela Filipa Narciso. *CONSEQUÊNCIAS DA UTILIZAÇÃO DE SUPLEMENTOS PROTEICOS PARA A DOENÇA RENAL.* 2020. 66 f. Dissertação (Mestrado) - Curso de Farmácia, Instituto Universitário Egas Moniz, Pais Portugal, 2020. Cap. 01. Disponível em: https://comum.rcaap.pt/bitstream/10400.26/35096/1/Paix%C3%A3o_Daniela_Filipa_Narciso.pdf f. Acesso em: 08 jul. 2023.

Wong L, Duque G, McMahon LP. Sarcopenia e fragilidade: desafios na prática nefrológica convencional. *Rim Int Rep.* 2021 Jun 12; 6(10):2554-2564. DOI: 10.1016/j.ekir.2021.05.039. PMID: 34622096; PMCID: PMC8484128.

Noce A, Marrone G, Ottaviani E, Guerriero C, Di Daniele F, Pietroboni Zaitseva A, Di Daniele N. Uremic Sarcopenia and Its Possible Nutritional Approach. *Nutrients.* 2021 Jan 4;13(1):147. doi: 10.3390/nu13010147. PMID: 33406683; PMCID: PMC7824031.

Sabatino, Alice, *et al.* Sarcopenia na doença renal crônica: o que aprendemos até agora? *Journal of Nephrology*, doi: 10.1007/S40620-020-00840-Y (2021).

Peruchi, Rachel Fernanda Pecego, Karina Ruíz, Sabrina de Almeida Marques and Luiz Fernando Moraes Moreira. “SUPLEMENTAÇÃO NUTRICIONAL EM IDOSOS (AMINOÁCIDOS, PROTEÍNAS, PUFAS, VITAMINA D E ZINCO) COM ÊNFASE EM SARCOPENIA: UMA REVISÃO SISTEMÁTICA.” (2018).



SOUZA, V. A. DE . et al.. Sarcopenia na doença renal crônica. *Brazilian Journal of Nephrology*, v. 37, n. 1, p. 98–105, jan. 2015. <https://doi.org/10.5935/0101-2800.20150014>

MOURA, Gisele Viana de. Uso de suplementos alimentares no manejo nutricional em idosos com Sarcopenia. *Saúde.Com*, [S.L.], v. 17, n. 3, p. 1-8, 27 set. 2021. Universidade Estadual do Sudoeste da Bahia/Edições UESB. <http://dx.doi.org/10.22481/rsc.v17i3.8142>. Disponível em: https://www.researchgate.net/publication/355133640_Uso_de_suplementos_alimentares_no_manejo_nutricional_em_idosos_com_Sarcopenia. Acesso em: 28 set. 2023

YU, Ming-Dian et al. Relação entre doença renal crônica e sarcopenia. *Reseah Square*, [s. l], p. 1-21, fev. 2021. Disponível em: <https://www.researchsquare.com/article/rs-280904/v1>. Acesso em: 08 jul. 2023.

March DS, Wilkinson TJ, Burnell T, Billany RE, Jackson K, Baker LA, Thomas A, Robinson KA, Watson EL, Graham-Brown MPM, Jones AW, Burton JO. The Effect of Non-Pharmacological and Pharmacological Interventions on Measures Associated with Sarcopenia in End-Stage Kidney Disease: A Systematic Review and Meta-Analysis. *Nutrients*. 2022 Apr 27;14(9):1817. doi: 10.3390/nu14091817. PMID: 35565785; PMCID: PMC9101978.

BEASLEY, Jeannette M.; SHIKANY, James M.; THOMSON, Cynthia A.. The Role of Dietary Protein Intake in the Prevention of Sarcopenia of Aging. *Nutrition In Clinical Practice*, [S.L.], v. 28, n. 6, p. 684-690, 25 out. 2013. Wiley. <http://dx.doi.org/10.1177/0884533613507607>.

TELLES, Cristina et al. IMPORTÂNCIA DA TERAPIA NUTRICIONAL COM ÊNFASE NO CÁLCIO, FÓSFORO E POTÁSSIO NO TRATAMENTO DA DOENÇA RENAL CRÔNICA. *Perspectiva*, Erechim - Rs, v. 39, p. 1-12, 01 mar. 2015. Disponível em: https://www.uricer.edu.br/site/pdfs/perspectiva/145_489.pdf. Acesso em: 19 out. 2023.